MedPath
HSA Approval

HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4ML

SIN17117P

HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4ML

HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4ML

October 17, 2024

SANDOZ SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSANDOZ SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

SUBCUTANEOUS

Medical Information

L04AB04

Manufacturer Information

SANDOZ SINGAPORE PTE. LTD.

Novartis Pharmaceutical Manufacturing GmbH

Active Ingredients

Adalimumab

20 mg/0.4 mL

Adalimumab

Documents

Package Inserts

Hyrimoz PFS injection 20mg PI.pdf

Approved: October 17, 2024

Download

Patient Information Leaflets

Hyrimoz PFS injection 20mg PIL.pdf

Approved: October 17, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4ML - HSA Approval | MedPath